

# Geoff McCaughan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3105513/publications.pdf>

Version: 2024-02-01

484  
papers

23,122  
citations

7069

78  
h-index

12910

131  
g-index

496  
all docs

496  
docs citations

496  
times ranked

20027  
citing authors

#	ARTICLE	IF	CITATIONS
1	Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand. <i>Liver Transplantation</i> , 2022, 28, 236-246.	1.3	3
2	Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. <i>Drug and Alcohol Review</i> , 2022, 41, 706-714.	1.1	2
3	Those Donor Leucocytes Again? This Time It's VITT!. <i>Liver Transplantation</i> , 2022, 28, 164-166.	1.3	0
4	The molecular phenotypes of injury, steatohepatitis, and fibrosis in liver transplant biopsies in the INTERLIVER study. <i>American Journal of Transplantation</i> , 2022, 22, 909-926.	2.6	4
5	Deletion of kif3a in CK19 positive cells leads to primary cilia loss, biliary cell proliferation and cystic liver lesions in TAA-treated mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166335.	1.8	5
6	The Delay of Arterialization After Initial Portal Reperfusion More Than Warm Ischemia Time May Determine Ischemic-type Biliary Injury. <i>Transplantation</i> , 2022, 106, e167-e168.	0.5	0
7	The optimal immunosuppression management to prevent early rejection after liver transplantation: A systematic review of the literature and expert panel recommendations. <i>Clinical Transplantation</i> , 2022, 36, e14614.	0.8	5
8	Liver Endothelial Heg Regulates Vascular/Biliary Network Patterning and Metabolic Zonation Via Wnt Signaling. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1757-1783.	2.3	8
9	Validation of the <sc>aMAP</sc> score to predict hepatocellular carcinoma development in a cohort of alcohol-related cirrhosis patients. <i>Liver Cancer International</i> , 2022, 3, 99-104.	0.2	5
10	Is it safe to expand the indications for split liver transplantation in adults? A single-centre analysis of 155 in-situ splits. <i>Clinical Transplantation</i> , 2022, , e14673.	0.8	5
11	Expansion of Liver Transplantation Criteria for Hepatocellular Carcinoma from Milan to UCSF in Australia and New Zealand and Justification for Metroticket 2.0. <i>Cancers</i> , 2022, 14, 2777.	1.7	4
12	The liver contains distinct interconnected networks of <sc>CX3CR1</sc> <sup>+</sup> macrophages, <sc>XCR1</sc> <sup>+</sup> type 1 and <sc>CD301a</sc> <sup>+</sup> type 2 conventional dendritic cells embedded within portal tracts. <i>Immunology and Cell Biology</i> , 2022, 100, 394-408.	1.0	4
13	MELD-GRAIL and MELD-GRAIL-Na Are Not Superior to MELD or MELD-Na in Predicting Liver Transplant Waiting List Mortality at a Single-center Level. <i>Transplantation Direct</i> , 2022, 8, e1346.	0.8	3
14	The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand. <i>Transplantation Direct</i> , 2022, 8, e1345.	0.8	2
15	Adrenal Insufficiency in Cirrhosis: Don't Forget the Hypothalamus. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1074.	2.4	2
16	Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or re-diagnose infections is effective in Australia. <i>Journal of Viral Hepatitis</i> , 2021, 28, 121-128.	1.0	6
17	Beware of Portal Vein Thrombosis After Laparoscopic Sleeve Gastrectomy in Liver Transplant Recipients. <i>Liver Transplantation</i> , 2021, 27, 1066-1067.	1.3	3
18	DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 1637.	1.7	9

#	ARTICLE	IF	CITATIONS
19	An improved production and purification protocol for recombinant soluble human fibroblast activation protein alpha. <i>Protein Expression and Purification</i> , 2021, 181, 105833.	0.6	2
20	Drug-induced liver injury in Australia, 2009–2020: the increasing proportion of non-paracetamol cases linked with herbal and dietary supplements. <i>Medical Journal of Australia</i> , 2021, 215, 261-268.	0.8	18
21	Addressing the challenges of split liver transplantation through technical advances. A systematic review. <i>Transplantation Reviews</i> , 2021, 35, 100627.	1.2	11
22	Liberal Use of Interposition Grafts for Arterial Reconstruction Is Safe and Effective in Adult Split Liver Transplantation. <i>Transplantation Direct</i> , 2021, 7, e735.	0.8	3
23	Prevalence and Impact of Fatty Liver Disease in Adult Deceased Liver Transplant Donors: Metabolic-Associated Fatty Liver Disease or Nonalcoholic Fatty Liver Disease?. <i>Liver Transplantation</i> , 2021, 27, 1498-1501.	1.3	3
24	Prolonged Ex Vivo Normothermic Perfusion of a Split Liver. <i>Transplantation Direct</i> , 2021, 7, e763.	0.8	12
25	Steroid-refractory T-cell mediated rejection after human metapneumovirus infection in a liver transplant recipient. <i>Pathology</i> , 2021, 53, 793-794.	0.3	1
26	Quality of life indicators in hepatic encephalopathy following supplementation with branched chain amino acids and/or synbiotics: A post-hoc analysis. <i>GastroHep</i> , 2021, 3, 50-57.	0.3	0
27	Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 187.	5.8	209
28	Are split liver grafts a suitable option in high-risk liver transplant recipients?. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 675-680.	0.8	2
29	Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 5495.	1.7	15
30	Prevalence and outcomes of <i>Clostridioides difficile</i> infection in liver transplant recipients. <i>Transplant Infectious Disease</i> , 2021, , e13758.	0.7	3
31	A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2. <i>Molecules</i> , 2020, 25, 5392.	1.7	26
32	Differential Impact of Extended Criteria Donors After Brain Death or Circulatory Death in Adult Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1603-1617.	1.3	21
33	Efficacy and safety profile of calcineurin inhibitor salvage therapy in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1309-1317.	0.6	5
34	Emerging role of endoscopic ultrasound-guided liver biopsy. <i>Gut</i> , 2020, , gutjnl-2020-322704.	6.1	3
35	Induction Phase of Spontaneous Liver Transplant Tolerance. <i>Frontiers in Immunology</i> , 2020, 11, 1908.	2.2	7
36	Restoring the natural tropism of AAV2 vectors for human liver. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	41

#	ARTICLE	IF	CITATIONS
37	Animal and translational models of SARS-CoV-2 infection and COVID-19. <i>Mucosal Immunology</i> , 2020, 13, 877-891.	2.7	155
38	COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?. <i>Journal of Diabetes</i> , 2020, 12, 649-658.	0.8	124
39	Impact of Having a Planned Additional Operation at Time of Liver Transplant on Graft and Patient Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 608.	1.0	1
40	The molecular diagnosis of rejection in liver transplant biopsies: First results of the INTERLIVER study. <i>American Journal of Transplantation</i> , 2020, 20, 2156-2172.	2.6	30
41	Platelet activating factor receptor acts to limit colitis-induced liver inflammation. <i>FASEB Journal</i> , 2020, 34, 7718-7732.	0.2	14
42	Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 243-253.	1.8	45
43	Trp53 and Rb1 regulate autophagy and ligand-dependent Hedgehog signaling. <i>Journal of Clinical Investigation</i> , 2020, 130, 4006-4018.	3.9	10
44	IDDF2020-ABS-0162...Trends in hospitalised drug-induced liver injury from 2009 to 2019 – the rise of non-prescription medications. , 2020, , .		0
45	Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study. <i>Nutrients</i> , 2019, 11, 1810.	1.7	30
46	Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver. <i>Scientific Reports</i> , 2019, 9, 10596.	1.6	18
47	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986269.	1.4	75
48	CD147 mediates intrahepatic leukocyte aggregation and determines the extent of liver injury. <i>PLoS ONE</i> , 2019, 14, e0215557.	1.1	8
49	Letter: elderly AIH patients-an important subgroup. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 615-615.	1.9	0
50	APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. <i>Hepatology International</i> , 2019, 13, 649-661.	1.9	72
51	Immune regeneration in irradiated mice is not impaired by the absence of DPP9 enzymatic activity. <i>Scientific Reports</i> , 2019, 9, 7292.	1.6	4
52	Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1314-1322.	1.9	21
53	IDDF2019-ABS-0196...Long term outcomes of utilizing donation after circulatory death grafts in liver transplantation – an australian 12-year cohort study. , 2019, , .		0
54	IDDF2019-ABS-0220...Long-term outcomes of utilizing extended criteria deceased donors in liver transplantation – an australian 12-year cohort study. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Excellent Contemporary Graft Survival for Adult Liver Retransplantation: An Australian and New Zealand Registry Analysis From 1986 to 2017. <i>Transplantation Direct</i> , 2019, 5, e472.	0.8	14
56	Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. <i>Liver Transplantation</i> , 2019, 25, 25-34.	1.3	35
57	Identification of Novel Natural Substrates of Fibroblast Activation Protein-alpha by Differential Degradomics and Proteomics. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 65-85.	2.5	41
58	Molecular profiling of postreperfusion milieu determines acute kidney injury after liver transplantation: A prospective study. <i>Liver Transplantation</i> , 2018, 24, 922-931.	1.3	12
59	Novel TOF-MS Means of Quantifying ApoAI Amyloid Protein Load After Combined Liver Kidney Transplantation. <i>Transplantation</i> , 2018, 102, e192-e193.	0.5	0
60	Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 563-573.	2.0	50
61	Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 268-277.	2.4	39
62	Sclerosing peritonitis post liver transplantation: a rare condition where surgery is an important treatment option. <i>ANZ Journal of Surgery</i> , 2018, 88, E424-E428.	0.3	0
63	Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. <i>Liver Transplantation</i> , 2018, 24, 380-393.	1.3	101
64	Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (<scp>MELD</scp> <math>\geq 15</math>). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 401-411.	1.9	18
65	Deletion of sphingosine kinase 1 inhibits liver tumorigenesis in diethylnitrosamine-treated mice. <i>Oncotarget</i> , 2018, 9, 15635-15649.	0.8	19
66	Frailty in advanced liver disease. <i>Liver International</i> , 2018, 38, 2117-2128.	1.9	73
67	Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1061, 3-18.	0.8	22
68	Circulating Endothelial Progenitor Cells Present an Inflammatory Phenotype and Function in Patients With Alcoholic Liver Cirrhosis. <i>Frontiers in Physiology</i> , 2018, 9, 556.	1.3	16
69	Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 10283.	1.6	21
70	How to select the appropriate adjuvant therapy for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1167-1170.	0.9	9
71	Factors influencing donor and recipient decision making in adult-to-adult living donor liver transplantation: a survey of a non-transplant population. <i>ANZ Journal of Surgery</i> , 2017, 87, 177-181.	0.3	2
72	Postreperfusion microcirculatory derangements after liver transplantation: Relationship to hemodynamics, serum mediators, and outcome. <i>Liver Transplantation</i> , 2017, 23, 527-536.	1.3	20

#	ARTICLE	IF	CITATIONS
73	The RhoGAP protein ARHGAP18/SENEX localizes to microtubules and regulates their stability in endothelial cells. <i>Molecular Biology of the Cell</i> , 2017, 28, 1066-1078.	0.9	19
74	Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort. <i>Liver International</i> , 2017, 37, 442-448.	1.9	22
75	The pro-fibrotic role of dipeptidyl peptidase 4 in carbon tetrachloride-induced experimental liver injury. <i>Immunology and Cell Biology</i> , 2017, 95, 443-453.	1.0	32
76	Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e98.	1.3	83
77	Interactions between primary sclerosing cholangitis and inflammatory bowel disease: implications in the adult liver transplant setting. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 949-960.	1.4	5
78	Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. <i>Journal of Viral Hepatitis</i> , 2017, 24, 823-831.	1.0	107
79	An update on the pathophysiology and management of polycystic liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 569-581.	1.4	16
80	Can response to locoregional therapy help predict longterm survival after liver transplantation for hepatocellular carcinoma? A systematic review. <i>Liver Transplantation</i> , 2017, 23, 375-385.	1.3	16
81	Does Frailty Correlate With Sarcopenia in Patients With Cirrhosis and Portal Hypertension?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 156.	2.4	2
82	A Liver Capsular Network of Monocyte-Derived Macrophages Restricts Hepatic Dissemination of Intraperitoneal Bacteria by Neutrophil Recruitment. <i>Immunity</i> , 2017, 47, 374-388.e6.	6.6	171
83	The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	9
84	Aggressive nutrition intervention reduces ascites and frequency of paracentesis in malnourished patients with cirrhosis and ascites. <i>JGH Open</i> , 2017, 1, 92-97.	0.7	14
85	Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy. <i>Cancer Research</i> , 2017, 77, 4434-4447.	0.4	52
86	Have we significantly underestimated the capacity in the Australian health system to treat chronic hepatitis C infection in an interferon-free era?. <i>Internal Medicine Journal</i> , 2017, 47, 269-274.	0.5	5
87	Circulating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease. <i>PLoS ONE</i> , 2017, 12, e0178987.	1.1	16
88	Patients with non-viral liver disease have a greater tumor burden and less curative treatment options when diagnosed with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2763.	1.4	6
89	Prevalence and outcomes of pancreatic cystic neoplasms in liver transplant recipients. <i>World Journal of Gastroenterology</i> , 2017, 23, 8526-8532.	1.4	8
90	Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0155800.	1.1	54

#	ARTICLE	IF	CITATIONS
91	Circulating CD147 predicts mortality in advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 459-466.	1.4	14
92	Liver transplantation in Australia and New Zealand. <i>Liver Transplantation</i> , 2016, 22, 830-838.	1.3	37
93	Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1016-1024.	1.4	30
94	Divergent Inflammatory, Fibrogenic, and Liver Progenitor Cell Dynamics in Two Common Mouse Models of Chronic Liver Injury. <i>American Journal of Pathology</i> , 2016, 186, 1762-1774.	1.9	29
95	Dipeptidyl peptidase 9 enzymatic activity influences the expression of neonatal metabolic genes. <i>Experimental Cell Research</i> , 2016, 342, 72-82.	1.2	24
96	Alcoholic Liver Disease in Asia, Europe, and North America. <i>Gastroenterology</i> , 2016, 150, 1786-1797.	0.6	133
97	Assessment of adult patients with chronic liver failure for liver transplantation in 2015: who and when?. <i>Internal Medicine Journal</i> , 2016, 46, 404-412.	0.5	13
98	The CD8 T cell response during tolerance induction in liver transplantation. <i>Clinical and Translational Immunology</i> , 2016, 5, e102.	1.7	15
99	Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: A population-based cohort study in Australia. <i>British Journal of Haematology</i> , 2016, 174, 550-562.	1.2	22
100	Deletion of sphingosine kinase 1 ameliorates hepatic steatosis in diet-induced obese mice: Role of PPAR $\gamma$ . <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 138-147.	1.2	41
101	Neuropeptide Y is a physiological substrate of fibroblast activation protein: Enzyme kinetics in blood plasma and expression of Y2R and Y5R in human liver cirrhosis and hepatocellular carcinoma. <i>Peptides</i> , 2016, 75, 80-95.	1.2	32
102	Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Infectious Diseases</i> , 2016, 16, 685-697.	4.6	402
103	High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1144-1152.e6.	0.6	23
104	Effector T cell function rather than survival determines extent and duration of hepatitis in mice. <i>Journal of Hepatology</i> , 2016, 64, 1327-1338.	1.8	5
105	Accumulation of Deleterious Passenger Mutations Is Associated with the Progression of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0162586.	1.1	11
106	Hepatic artery stenosis after liver transplantation: Is endovascular treatment always necessary?. <i>Liver Transplantation</i> , 2015, 21, 162-168.	1.3	42
107	Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study. <i>Journal of Diabetes</i> , 2015, 7, 809-819.	0.8	44
108	Could The Morning After liver transplant be immunologically interesting?. <i>Liver Transplantation</i> , 2015, 21, 1120-1122.	1.3	0

#	ARTICLE	IF	CITATIONS
109	Percutaneous Retroperitoneal Splenorenal Shunt for Symptomatic Portal Vein Thrombosis After Liver Transplantation. <i>American Journal of Transplantation</i> , 2015, 15, 2261-2264.	2.6	10
110	Our experts highlight the most important research articles across the spectrum of topics relevant to the field of hepatic oncology. <i>Hepatic Oncology</i> , 2015, 2, 13-14.	4.2	0
111	Longitudinal dose and type of immunosuppression in a national cohort of Australian liver, heart, and lung transplant recipients, 1984-2006. <i>Clinical Transplantation</i> , 2015, 29, 978-990.	0.8	6
112	Analysis of Post-Liver Transplant Hepatitis C Virus Recurrence Using Serial Cluster of Differentiation Antibody Microarrays. <i>Transplantation</i> , 2015, 99, e120-e126.	0.5	7
113	Feasibility, acceptability and safety of a nurse led hepatitis B clinic based in the community. <i>Collegian</i> , 2015, 22, 233-240.	0.6	4
114	Immune outcomes in the liver: Is CD8 T cell fate determined by the environment?. <i>Journal of Hepatology</i> , 2015, 63, 1005-1014.	1.8	45
115	Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 466-472.	1.1	21
116	Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection. <i>Journal of Viral Hepatitis</i> , 2015, 22, 737-753.	1.0	73
117	Is there such a thing as protocol immunosuppression in liver transplantation?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1-4.	1.4	12
118	An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1240-1247.	1.2	30
119	Dipeptidyl peptidase 9 subcellular localization and a role in cell adhesion involving focal adhesion kinase and paxillin. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 470-480.	1.9	31
120	Suicidal emperipolesis: a process leading to cell-in-cell structures, T cell clearance and immune homeostasis.. <i>Current Molecular Medicine</i> , 2015, 15, 819-827.	0.6	31
121	Professor Bruce Hall and the ABC. <i>Medical Journal of Australia</i> , 2014, 201, 322-322.	0.8	0
122	Analysis of the intrahepatic ductular reaction and progenitor cell responses in hepatitis C virus recurrence after liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 1508-1519.	1.3	25
123	Novel Aspects of the Liver Microenvironment in Hepatocellular Carcinoma Pathogenesis and Development. <i>International Journal of Molecular Sciences</i> , 2014, 15, 9422-9458.	1.8	73
124	Liver transplantation outcomes for Australian Aboriginal and Torres Strait Islanders. <i>Liver Transplantation</i> , 2014, 20, 798-806.	1.3	6
125	Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1458-1462.	1.4	4
126	Advances in and the future of treatments for hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 633-647.	1.4	8



#	ARTICLE	IF	CITATIONS
127	Distribution of interferon lambda $\lambda$ 3 gene polymorphisms in <sc>A</sc>ustralian patients with previously untreated genotype 1 chronic hepatitis <sc>C</sc>: Analysis from the <sc>PREDICT</sc> and <sc>CHARIOT</sc> studies. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 179-184.	1.4	14
128	Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2540-9.	3.3	81
129	<i>ITPA</i> genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology, 2014, 59, 2152-2160.	3.6	25
130	Intrahepatic Activation of Naive CD4+ T Cells by Liver-Resident Phagocytic Cells. Journal of Immunology, 2014, 193, 2087-2095.	0.4	28
131	Quantitation of fibroblast activation protein (FAP) $\lambda$ specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio, 2014, 4, 43-54.	1.0	89
132	A rare variant in human fibroblast activation protein associated with ER stress, loss of enzymatic function and loss of cell surface localisation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1248-1259.	1.1	18
133	Beyond liver fibrosis: Hepatic stellate cell senescence links obesity to liver cancer by way of the microbiome. Hepatology, 2014, 59, 2413-2415.	3.6	18
134	Hepatocyte Produced Matrix Metalloproteinases Are Regulated by CD147 in Liver Fibrogenesis. PLoS ONE, 2014, 9, e90571.	1.1	42
135	Osteopontin is an important mediator of alcoholic liver disease<i>via</i>hepatic stellate cell activation. World Journal of Gastroenterology, 2014, 20, 13088.	1.4	44
136	Differential migration of passenger leukocytes and rapid deletion of naive alloreactive CD8 T cells after mouse liver transplantation. Liver Transplantation, 2013, 19, 1224-1235.	1.3	25
137	Early hepatocellular carcinoma $\lambda$ Is there such a thing as too early?. Journal of Hepatology, 2013, 58, 210-211.	1.8	2
138	Operational tolerance in liver transplantation: Shall we predict or promote?. Liver Transplantation, 2013, 19, 933-936.	1.3	7
139	Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients. American Journal of Transplantation, 2013, 13, 174-183.	2.6	81
140	Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. Journal of Hepatology, 2013, 58, 467-472.	1.8	71
141	$\lambda$ œNo one really knows why they are alive until they know what they'd die for $\lambda$ Lessons from the death of a living liver donor. Liver Transplantation, 2013, 19, 1169-1171.	1.3	3
142	Current Management of HBV Pre and Post Liver Transplant. Current Hepatitis Reports, 2013, 12, 119-123.	0.3	0
143	$\lambda$ œTesting your methyl $\lambda$ œ DNA methylation profiling of serum DNA of HCC patients. Hepatology International, 2013, 7, 785-787.	1.9	1
144	Author reply. Internal Medicine Journal, 2013, 43, 607-607.	0.5	0

#	ARTICLE	IF	CITATIONS
145	Terlipressin therapy for moderate-to-severe hyponatraemia in patients with liver failure. <i>Internal Medicine Journal</i> , 2013, 43, 240-246.	0.5	10
146	De novo Cancer-Related Death in Australian Liver and Cardiothoracic Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 1296-1304.	2.6	69
147	Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27. <i>Blood</i> , 2013, 122, 2911-2919.	0.6	60
148	Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. <i>Liver Transplantation</i> , 2013, 19, 268-274.	1.3	81
149	De novo malignant disease after liver transplantation? Risk and surveillance strategies. <i>Liver Transplantation</i> , 2013, 19, S62-S67.	1.3	15
150	Hepatitis C Virus-Associated Cholestatic Hepatitis: We Cannot Seem to Agree on Diagnostic Criteria. <i>Liver Transplantation</i> , 2013, 19, 115-117.	1.3	7
151	Gene Therapy for Tolerance. <i>Transplantation</i> , 2013, 95, 70-77.	0.5	19
152	Nature and outcomes of the increased incidence of colorectal malignancy after liver transplantation in Australasia. <i>Medical Journal of Australia</i> , 2013, 199, 610-612.	0.8	14
153	An International Comparison of the Effect of Policy Shifts to Organ Donation following Cardiocirculatory Death (DCD) on Donation Rates after Brain Death (DBD) and Transplantation Rates. <i>PLoS ONE</i> , 2013, 8, e62010.	1.1	62
154	Pentoxifylline-induced drug rash with eosinophilia and systemic symptoms (DRESS) in a patient with caffeine intolerance. <i>Journal of Dermatological Case Reports</i> , 2013, 7, 77-81.	1.1	4
155	Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver. <i>World Journal of Gastroenterology</i> , 2013, 19, 2883-2893.	1.4	33
156	Cancer Risk After Organ Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 663-663.	3.8	7
157	Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients. <i>Antiviral Therapy</i> , 2012, 17, 849-854.	0.6	2
158	Analysis of human liver disease using a cluster of differentiation (CD) antibody microarray. <i>Liver International</i> , 2012, 32, 1527-1534.	1.9	12
159	Trekking new ground: Overcoming medical and social impediments for extended criteria liver transplant recipients. <i>Liver Transplantation</i> , 2012, 18, S39-S46.	1.3	10
160	New therapies against HCV: Expected risks and challenges associated with their use in the liver transplant setting. <i>Journal of Hepatology</i> , 2012, 57, 1361-1367.	1.8	11
161	Two lymph nodes draining the mouse liver are the preferential site of DC migration and T cell activation. <i>Journal of Hepatology</i> , 2012, 57, 352-358.	1.8	46
162	Naïve CD8 T cell activation by liver bone marrow-derived cells leads to a neglected IL-2low Bimhigh phenotype, poor CTL function and cell death. <i>Journal of Hepatology</i> , 2012, 57, 830-836.	1.8	27

#	ARTICLE	IF	CITATIONS
163	Tolerance in liver transplantation. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 73-84.	1.0	30
164	Expression of common gamma chain signalling cytokines and their receptors distinguishes rejection from tolerance in a rat organ transplant model. <i>Transplant Immunology</i> , 2012, 27, 89-94.	0.6	7
165	Is the end of chronic hepatitis C virus infection in sight?. <i>Medical Journal of Australia</i> , 2012, 196, 614-614.	0.8	1
166	APASL consensus statements and management algorithms for hepatitis C virus infection. <i>Hepatology International</i> , 2012, 6, 409-435.	1.9	152
167	A case of portopulmonary hypertension spanning 18 years: successful use of bosentan for progressive disease after two liver transplantations. <i>Internal Medicine Journal</i> , 2012, 42, 600-601.	0.5	1
168	Discoidin Domain Receptor 1. <i>American Journal of Pathology</i> , 2011, 178, 1134-1144.	1.9	32
169	Pathogenesis of cholestatic hepatitis C. <i>Journal of Hepatology</i> , 2011, 54, 392-394.	1.8	16
170	Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2011, 55, 435-444.	1.8	83
171	Spontaneous acceptance of mouse kidney allografts is associated with increased Foxp3 expression and differences in the B and T cell compartments. <i>Transplant Immunology</i> , 2011, 24, 149-156.	0.6	29
172	Operational Tolerance in Organ Transplantation Versus Tissue Engineering: Into the Future. <i>Transplantation</i> , 2011, 92, e39.	0.5	4
173	Approaching the Promise of Operational Tolerance in Clinical Transplantation. <i>Transplantation</i> , 2011, 91, 1065-1074.	0.5	40
174	Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients. <i>Antiviral Therapy</i> , 2011, 16, 173-180.	0.6	1
175	Soluble CD26 Dipeptidyl Peptidase IV Enhances Human Lymphocyte Proliferation <i>In Vitro</i> Independent of Dipeptidyl Peptidase Enzyme Activity and Adenosine Deaminase Binding. <i>Scandinavian Journal of Immunology</i> , 2011, 73, 102-111.	1.3	54
176	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. <i>Liver International</i> , 2011, 31, 61-80.	1.9	481
177	Prevention of post liver transplant HBV recurrence. <i>Hepatology International</i> , 2011, 5, 876-881.	1.9	3
178	Liver transplantation and hepatitis C: Will understanding the interleukin-28B polymorphisms improve outcomes?. <i>Liver Transplantation</i> , 2011, 17, 219-221.	1.3	5
179	Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation?. <i>Liver Transplantation</i> , 2011, 17, S133-S138.	1.3	19
180	Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. <i>Hepatology</i> , 2011, 53, 1109-1117.	3.6	37

#	ARTICLE	IF	CITATIONS
181	Sinusoidal endothelium is essential for liver regeneration. <i>Hepatology</i> , 2011, 54, 731-733.	3.6	10
182	Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?. <i>Hepatology</i> , 2011, 54, 1998-2004.	3.6	125
183	The long and the short of interferon-gamma-inducible protein 10 in hepatitis C virus infection. <i>Hepatology</i> , 2011, 54, 1875-1879.	3.6	3
184	Hepatocyte entry leads to degradation of autoreactive CD8 T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16735-16740.	3.3	137
185	A Novel Role of Dipeptidyl Peptidase 9 in Epidermal Growth Factor Signaling. <i>Molecular Cancer Research</i> , 2011, 9, 948-959.	1.5	58
186	Targeting Dipeptidyl Peptidase-4 (DPP-4) and Fibroblast Activation Protein (FAP) for Diabetes and Cancer Therapy. <i>RSC Drug Discovery Series</i> , 2011, , 118-144.	0.2	5
187	Snipping away at hepatitis C. <i>Hepatology</i> , 2010, 51, 703-705.	3.6	3
188	Minimal but significant improvement in survival for non-hepatitis C-related adult liver transplant patients beyond the one-year posttransplant mark. <i>Liver Transplantation</i> , 2010, 16, 130-137.	1.3	19
189	Improvement in hepatopulmonary syndrome after methadone withdrawal: A case report with implications for disease mechanism. <i>Liver Transplantation</i> , 2010, 16, 870-873.	1.3	7
190	The dipeptidyl peptidase IV family in cancer and cell biology. <i>FEBS Journal</i> , 2010, 277, 1126-1144.	2.2	149
191	Locoregional therapies for hepatocellular carcinoma: Which patients are most likely to gain a survival advantage?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1299-1305.	1.4	4
192	Increasing liver transplantation waiting list mortality: a report from the Australian National Liver Transplantation Unit, Sydney. <i>Internal Medicine Journal</i> , 2010, 40, 619-625.	0.5	14
193	Isolated liver transplantation in children with cystic fibrosis - An Australian experience. <i>Pediatric Transplantation</i> , 2010, 14, 779-785.	0.5	18
194	Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 123-135.e2.	0.6	157
195	Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing. <i>Journal of Hepatology</i> , 2010, 53, 616-623.	1.8	42
196	Donor IL-4-treatment induces alternatively activated liver macrophages and IDO-expressing NK cells and promotes rat liver allograft acceptance. <i>Transplant Immunology</i> , 2010, 22, 172-178.	0.6	24
197	The In Vivo Expression of Dipeptidyl Peptidases 8 and 9. <i>Journal of Histochemistry and Cytochemistry</i> , 2009, 57, 1025-1040.	1.3	88
198	Gene therapy in transplantation. <i>Transplantation Reviews</i> , 2009, 23, 159-170.	1.2	8

#	ARTICLE	IF	CITATIONS
199	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. <i>Hepatology</i> , 2009, 49, 1069-1082.	3.6	131
200	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , 2009, 50, 1017-1029.	3.6	60
201	Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trial. <i>Hepatology</i> , 2009, 50, 1045-1055.	3.6	60
202	Overexpression of indoleamine dioxygenase in rat liver allografts using a high-efficiency adeno-associated virus vector does not prevent acute rejection. <i>Liver Transplantation</i> , 2009, 15, 233-241.	1.3	19
203	Usage and outcomes of deceased donor liver allografts with preprocurement injury from blunt trauma. <i>Liver Transplantation</i> , 2009, 15, 321-325.	1.3	17
204	Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 709-718.	1.3	51
205	Donor and recipient selection leads to good patient and graft outcomes for right lobe split transplantation versus whole graft liver transplantation in adult recipients. <i>Liver Transplantation</i> , 2009, 15, 1586-1593.	1.3	22
206	The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997-2006. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1648-1654.	1.4	56
207	Bone marrow stem cells and the liver: Are they relevant?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1608-1616.	1.4	17
208	Advances in viral hepatitis: 50 years of Australian gastroenterology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, S132-5.	1.4	2
209	Molecular and Cellular Aspects of Hepatitis C Virus Reinfection After Liver Transplantation: How the Early Phase Impacts on Outcomes. <i>Transplantation</i> , 2009, 87, 1105-1111.	0.5	33
210	Hepatitis B and Liver Transplantation. , 2009, , 145-167.		0
211	Inflammation and Repair in Viral Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1468-1487.	1.1	31
212	Hepatocellular carcinoma development requires hepatic stem cells with altered transforming growth factor and interleukin-6 signaling. <i>Hepatology</i> , 2008, 47, 2134-2136.	3.6	11
213	A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. <i>Hepatology</i> , 2008, 48, 1460-1466.	3.6	149
214	Fibroblast activation protein and chronic liver disease. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 3168.	3.0	61
215	Intrahepatic Murine CD8 T-Cell Activation Associates With a Distinct Phenotype Leading to Bim-Dependent Death. <i>Gastroenterology</i> , 2008, 135, 989-997.	0.6	114
216	Direct effects of alcohol on hepatic fibrinolytic balance: Implications for alcoholic liver disease. <i>Journal of Hepatology</i> , 2008, 48, 614-627.	1.8	48

#	ARTICLE	IF	CITATIONS
217	Adrenal insufficiency and liver disease – Re-search. <i>Journal of Hepatology</i> , 2008, 48, 1018.	1.8	1
218	Heart allograft acceptance induced by anti-CD3 antibody in high-responder rats: Effect on foxp3 and cytokine expression and graft infiltration. <i>Transplant Immunology</i> , 2008, 19, 20-24.	0.6	5
219	The role of sphingosine kinase 1 in cancer: Oncogene or non-oncogene addiction?. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2008, 1781, 442-447.	1.2	135
220	Blocking Indoleamine Dioxygenase Activity Early After Rat Liver Transplantation Prevents Long-Term Survival But Does Not Cause Acute Rejection. <i>Transplantation</i> , 2008, 85, 1357-1361.	0.5	20
221	Liver Tolerance and the Manipulation of Immune Outcomes. <i>Inflammation and Allergy: Drug Targets</i> , 2008, 7, 6-18.	1.8	14
222	Use of Severely Steatotic Grafts in Liver Transplantation. <i>Annals of Surgery</i> , 2008, 248, 142-143.	2.1	2
223	Immunological Parameters Influencing Adaptive Immune Responses to the Hepatitis C Virus. , 2008, , 39-70.		0
224	The Liver: A Special Case in Transplantation Tolerance. <i>Seminars in Liver Disease</i> , 2007, 27, 194-213.	1.8	143
225	Simultaneous Vascularized Bone Marrow Transplantation to Promote Acceptance of Hind Limb Allografts and Its Effects on Central and Peripheral Chimerism. <i>Transplantation</i> , 2007, 83, 1273-1276.	0.5	11
226	Marked changes of the hepatic sinusoid in a transgenic mouse model of acute immune-mediated hepatitis. <i>Journal of Hepatology</i> , 2007, 46, 239-246.	1.8	48
227	Effect of Ascites on Bone Density Measurement in Cirrhosis. <i>Journal of Clinical Densitometry</i> , 2007, 10, 391-394.	0.5	22
228	Lamivudine Plus Low-Dose Hepatitis B Immunoglobulin to Prevent Recurrent Hepatitis B Following Liver Transplantation. <i>Gastroenterology</i> , 2007, 132, 931-937.	0.6	261
229	Liver fibrosis: a balance of ACEs?. <i>Clinical Science</i> , 2007, 113, 109-118.	1.8	103
230	Treatment for cirrhosis-associated hyponatremia? Vaptans and aquaresis. <i>Hepatology</i> , 2007, 45, 1080-1081.	3.6	2
231	Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. <i>Hepatology</i> , 2007, 46, 66-73.	3.6	122
232	“I’ll never touch it again, doctor!” harmful drinking after liver transplantation. <i>Hepatology</i> , 2007, 46, 1302-1304.	3.6	5
233	Intrahepatic interferon-stimulated gene responses: Can they predict treatment responses in chronic hepatitis C infection?. <i>Hepatology</i> , 2007, 46, 1326-1328.	3.6	9
234	Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 615-633.	1.4	144

#	ARTICLE	IF	CITATIONS
235	Combination adefovir/lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1500-1505.	1.4	15
236	Up-regulation of proliferative genes and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis. <i>Liver International</i> , 2007, 27, 960-968.	1.9	21
237	Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. <i>Liver International</i> , 2007, 27, 1240-1248.	1.9	22
238	Immune-mediated hepatitis drives low-level fusion between hepatocytes and adult bone marrow cells. <i>Journal of Hepatology</i> , 2006, 44, 334-341.	1.8	14
239	Intrahepatic gene expression in human alcoholic hepatitis. <i>Journal of Hepatology</i> , 2006, 45, 306-320.	1.8	65
240	Zoledronic Acid Prevents Bone Loss after Liver Transplantation. <i>Annals of Internal Medicine</i> , 2006, 144, 239.	2.0	144
241	The hepatic transcriptome in human liver disease. <i>Comparative Hepatology</i> , 2006, 5, 6.	0.9	25
242	Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. <i>Clinical Transplantation</i> , 2006, 20, 369-373.	0.8	46
243	Liver biopsy: is it still relevant?. <i>Internal Medicine Journal</i> , 2006, 36, 689-691.	0.5	18
244	Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. <i>FEBS Journal</i> , 2006, 273, 2447-2460.	2.2	66
245	Molecular characterization of a novel dipeptidyl peptidase like 2-short form (DPL2-s) that is highly expressed in the brain and lacks dipeptidyl peptidase activity. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2006, 1764, 33-43.	1.1	22
246	T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. <i>Hepatology</i> , 2006, 44, 1182-1190.	3.6	252
247	Gene array analysis of a rat model of liver transplant tolerance identifies increased complement C3 and the STAT-1/IRF-1 pathway during tolerance induction. <i>Liver Transplantation</i> , 2006, 12, 636-643.	1.3	18
248	Hereditary lysozyme amyloidosis: Spontaneous hepatic rupture (15 years apart) in mother and daughter. role of emergency liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 1152-1155.	1.3	22
249	PREDICTORS OF RELAPSE TO HARMFUL ALCOHOL AFTER ORTHOTOPIC LIVER TRANSPLANTATION. <i>Alcohol and Alcoholism</i> , 2006, 41, 278-283.	0.9	113
250	Extra-Enzymatic Roles of DPIV and FAP in Cell Adhesion and Migration on Collagen and Fibronectin. , 2006, 575, 213-222.		10
251	Vitamin D replacement for cirrhosis-related bone disease. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 689-699.	1.7	40
252	Structure and Function in Dipeptidyl Peptidase IV and Related Proteins. , 2006, 575, 45-54.		23

#	ARTICLE	IF	CITATIONS
253	DP8 and DP9 have Extra-Enzymatic Roles in Cell Adhesion, Migration and Apoptosis. , 2006, 575, 63-72.		5
254	Immunology and Immunosuppression. , 2006, , 621-642.		0
255	Posttransplant Interleukin-4 Treatment Converts Rat Liver Allograft Tolerance to Rejection. Transplantation, 2005, 79, 1116-1120.	0.5	13
256	Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Liver International, 2005, 25, 518-526.	1.9	14
257	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver International, 2005, 25, 472-489.	1.9	313
258	Liver transplantation utilizing pediatric cadaver donor livers. Pediatric Transplantation, 2005, 9, 47-51.	0.5	4
259	Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV. Journal of Cellular Physiology, 2005, 204, 687-692.	2.0	45
260	Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology, 2005, 42, 935-945.	3.6	159
261	Early intrahepatic antigen-specific retention of na <sup>+</sup> ve CD8+T cells is predominantly ICAM-1/LFA-1 dependent in mice. Hepatology, 2005, 42, 1063-1071.	3.6	51
262	Current approaches to the diagnosis and management of hepatocellular carcinoma. Clinical and Experimental Medicine, 2005, 5, 1-13.	1.9	16
263	Parenchymal Expression of CD86/B7.2 Contributes to Hepatitis C Virus-Related Liver Injury. Journal of Virology, 2005, 79, 10730-10739.	1.5	17
264	Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection. Clinical Chemistry, 2005, 51, 1867-1873.	1.5	482
265	Liver transplantation for viral hepatitis. British Journal of Hospital Medicine (London, England: 2005), 2005, 66, 08-12.	0.2	0
266	Intrahepatic immunity: a tale of two sites?. Trends in Immunology, 2005, 26, 512-517.	2.9	104
267	Donor Leukocytes Combine With Immunosuppressive Drug Therapy to Prolong Limb Allograft Survival. Transplantation Proceedings, 2005, 37, 2382-2384.	0.3	3
268	Donor Leukocytes Combined With Delayed Immunosuppressive Drug Therapy Prolong Limb Allograft Survival. Transplantation Proceedings, 2005, 37, 4630-4633.	0.3	1
269	Fibrosis progression in chronic hepatitis C virus infection. Gut, 2004, 53, 318-321.	6.1	84
270	Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPiV-like peptidase activity. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2004, 1679, 18-28.	2.4	116



#	ARTICLE	IF	CITATIONS
271	CASE REPORT: "Pinworm" Infection of the Liver: Unusual CT Appearance Leading to Hepatic Resection. <i>Digestive Diseases and Sciences</i> , 2004, 49, 466-468.	1.1	8
272	Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. <i>Hepatology</i> , 2004, 39, 1239-1247.	3.6	175
273	Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesis. <i>Hepatology</i> , 2004, 39, 1655-1662.	3.6	108
274	A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. <i>Liver Transplantation</i> , 2004, 10, 52-57.	1.3	79
275	Increased mononuclear cell activation and apoptosis early after human liver transplantation is associated with a reduced frequency of acute rejection. <i>Liver Transplantation</i> , 2004, 10, 397-403.	1.3	5
276	Non-Oxidative Metabolism of Ethanol by Rat Pancreatic Acini. <i>Pancreatology</i> , 2004, 4, 82-89.	0.5	45
277	Experimental limb transplantation, part III: Induction of tolerance in the rigorous strain combination of Brown Norway donor to Lewis recipient. <i>Transplantation Proceedings</i> , 2004, 36, 3276-3282.	0.3	10
278	Combined donor leucocyte administration and immunosuppressive drug treatment for survival of rat heart allografts. <i>Transplant Immunology</i> , 2004, 13, 177-184.	0.6	8
279	Mechanisms of HCV reinfection and allograft damage after liver transplantation. <i>Journal of Hepatology</i> , 2004, 40, 368-374.	1.8	94
280	Molecular Approaches to the Side Effects of Immunosuppressive Drugs. <i>Transplantation</i> , 2004, 78, 1114-1115.	0.5	9
281	Immunosuppression for HCV Following Liver Transplantation: Enough Is Just Enough. <i>Transplantation</i> , 2004, 78, 1413-1414.	0.5	7
282	Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 506-515.	1.0	54
283	The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. <i>Journal of Clinical Investigation</i> , 2004, 114, 701-712.	3.9	247
284	The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. <i>Journal of Clinical Investigation</i> , 2004, 114, 701-712.	3.9	132
285	Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. <i>Hepatology</i> , 2003, 38, 577-588.	3.6	48
286	Liver transplantation for HCV-associated liver cirrhosis: Predictors of outcomes in a population with significant genotype 3 and 4 distribution. <i>Liver Transplantation</i> , 2003, 9, 339-347.	1.3	60
287	Hepatitis C virus quasispecies: Misunderstood and mistreated?. <i>Liver Transplantation</i> , 2003, 9, 1048-1052.	1.3	6
288	Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. <i>Liver Transplantation</i> , 2003, 9, S21-S27.	1.3	40

#	ARTICLE	IF	CITATIONS
289	The heterogeneity of bone disease in cirrhosis: a multivariate analysis. <i>Osteoporosis International</i> , 2003, 14, 987-994.	1.3	41
290	Pathogenesis and management of alcoholic hepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1332-1344.	1.4	61
291	Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. <i>Gastroenterology</i> , 2003, 125, 1695-1704.	0.6	681
292	Structural Requirements for Catalysis, Expression, and Dimerization in the CD26/DPIV Gene Family. <i>Biochemistry</i> , 2003, 42, 694-701.	1.2	67
293	Gene Expression Profiling of Alcoholic Liver Disease in the Baboon ( <i>Papio hamadryas</i> ) and Human Liver. <i>American Journal of Pathology</i> , 2003, 163, 2303-2317.	1.9	78
294	Incisional hernia following orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 2003, 35, 425-426.	0.3	23
295	SMART amplification maintains representation of relative gene expression: quantitative validation by real time PCR and application to studies of alcoholic liver disease in primates. <i>Journal of Proteomics</i> , 2003, 55, 53-66.	2.4	61
296	Pharmacotherapy of hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2175-2185.	0.9	3
297	Intrahepatic Expression of Collagen and Fibroblast Activation Protein (FAP) in Hepatitis C Virus Infection. , 2003, 524, 235-243.		19
298	Dipeptidyl Peptidase IV Gene Family. , 2003, 524, 79-86.		24
299	Molecular Chimeras and Mutational Analysis in the Prolyl Oligopeptidase Gene Family. , 2003, 524, 49-55.		0
300	Postoperative administration of donor B cells induces rat kidney allograft acceptance: lack of association with TH2 cytokine expression in long-term accepted grafts1. <i>Transplantation</i> , 2002, 73, 1123-1130.	0.5	22
301	Insights into the Pathobiology of Hepatitis C Virus-Associated Cirrhosis. <i>American Journal of Pathology</i> , 2002, 160, 641-654.	1.9	172
302	Cytokine-dependent bystander hepatitis due to intrahepatic murine CD8+ T-cell activation by bone marrowâ€derived cells. <i>Gastroenterology</i> , 2002, 123, 1252-1264.	0.6	82
303	Time course of upregulation of fibrogenic growth factors and cellular infiltration in a rodent model of chronic renal allograft rejection. <i>Transplant Immunology</i> , 2002, 10, 245-254.	0.6	13
304	Gene array analysis and the liver. <i>Hepatology</i> , 2002, 36, 1313-1325.	3.6	46
305	Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. <i>Liver</i> , 2002, 22, 93-101.	0.1	111
306	Role of primary intrahepatic T-cell activation in the â€liver tolerance effectâ€™. <i>Immunology and Cell Biology</i> , 2002, 80, 84-92.	1.0	130

#	ARTICLE	IF	CITATIONS
307	Hepatocellular carcinoma: current approaches to diagnosis and management. <i>Internal Medicine Journal</i> , 2002, 32, 394-400.	0.5	19
308	Spontaneous acceptance of liver transplants in rodents: Evidence that liver leucocytes induce recipient T-cell death by neglect. <i>Immunology and Cell Biology</i> , 2002, 80, 93-100.	1.0	46
309	Fifty years of gastroenterology in Australia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 14, 179-193.	1.4	1
310	Journal of Gastroenterology and Hepatology celebrates the first Asia-Pacific Digestive Week, Sydney, September 2001. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, 353-354.	1.4	0
311	Withdrawal of immunosuppression in liver transplant recipients: Is this as good as it gets?. <i>Liver Transplantation</i> , 2002, 8, 408-410.	1.3	15
312	Intrahepatic cytokine profiles associated with posttransplantation hepatitis C virus[ndash ]related liver injury. <i>Liver Transplantation</i> , 2002, 8, 292-301.	1.3	66
313	Pathogenesis of hepatitis C virus recurrence in the liver allograft. <i>Liver Transplantation</i> , 2002, 8, S7-S13.	1.3	55
314	Gene array analysis and the liver. <i>Hepatology</i> , 2002, 36, 1313-1325.	3.6	20
315	Expression of growth arrest???specific gene 6 and its receptors in a rat model of chronic renal transplant rejection. <i>Transplantation</i> , 2002, 73, 657-660.	0.5	25
316	Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. <i>Life Sciences</i> , 2001, 68, 785-797.	2.0	40
317	Adult living donor liver transplantation: another Pandora's box?. <i>Medical Journal of Australia</i> , 2001, 175, 179-180.	0.8	5
318	Cytokines and chemokines in the immune response to hepatitis C infection. <i>Current Opinion in Infectious Diseases</i> , 2001, 14, 279-287.	1.3	43
319	CD26: A Multifunctional Integral Membrane and Secreted Protein of Activated Lymphocytes. <i>Scandinavian Journal of Immunology</i> , 2001, 54, 249-264.	1.3	326
320	Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. <i>Immunology and Cell Biology</i> , 2001, 79, 213-221.	1.0	261
321	To MELD or not to MELD?. <i>Hepatology</i> , 2001, 34, 215-215.	3.6	26
322	Immune activation is required for the induction of liver allograft tolerance: Implications for immunosuppressive therapy. <i>Liver Transplantation</i> , 2001, 7, 161-172.	1.3	55
323	Alcohol and the Pancreas. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 244S-250S.	1.4	13
324	Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. <i>Gut</i> , 2001, 49, 565-576.	6.1	135

#	ARTICLE	IF	CITATIONS
325	Posttransplant Administration of Donor Leukocytes Induces Long-Term Acceptance of Kidney or Liver Transplants by an Activation-Associated Immune Mechanism. <i>Journal of Immunology</i> , 2001, 166, 5258-5264.	0.4	43
326	Antigen-Specific Primary Activation of CD8+ T Cells Within the Liver. <i>Journal of Immunology</i> , 2001, 166, 5430-5438.	0.4	192
327	Alcohol and the pancreas. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 244S-250S.	1.4	4
328	A SHORT COURSE OF METHYLPREDNISOLONE IMMUNOSUPPRESSION INHIBITS BOTH REJECTION AND SPONTANEOUS ACCEPTANCE OF RAT LIVER ALLOGRAFTS. <i>Transplantation</i> , 2001, 72, 44-51.	0.5	57
329	Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. <i>FEBS Journal</i> , 2000, 267, 6140-6150.	0.2	234
330	LIVER TRANSPLANTATION IN PATIENTS WITH TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNTS. <i>ANZ Journal of Surgery</i> , 2000, 70, 493-495.	0.3	19
331	Hepatitis C in injecting drug-using women during and after pregnancy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 175-181.	1.4	32
332	Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 227-229.	1.4	3
333	East meets West: Acute liver failure in the global village. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 467-469.	1.4	11
334	Asian perspectives on viral hepatitis: Hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, G90-G93.	1.4	21
335	Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. <i>Transplant Infectious Disease</i> , 2000, 2, 166-185.	0.7	31
336	Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. <i>Immunological Reviews</i> , 2000, 174, 172-191.	2.8	77
337	Experimental autoimmune cholangitis: a mouse model of immune-mediated cholangiopathy. <i>Liver International</i> , 2000, 20, 351-356.	1.9	34
338	Therapies for chronic hepatitis B: emerging roles for nucleoside analogues. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 556-558.	0.5	2
339	Emerging therapies for hepatitis C virus (HCV) infection: the importance of HCV genotype. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 644-646.	0.5	1
340	Combination Low-Dose Hepatitis B Immune Globulin and Lamivudine Therapy Provides Effective Prophylaxis Against Posttransplantation Hepatitis B. <i>Liver Transplantation</i> , 2000, 6, 429-433.	1.3	228
341	Spontaneous Clearance of Hepatitis C Virus Infection Post-Liver Transplantation Is Associated With Rapidly Changing Quasispecies: A Single Case Report. <i>Liver Transplantation</i> , 2000, 6, 648-653.	1.3	25
342	Pancreatitis in adult orthotopic liver allograft recipients: Risk factors and outcome. <i>Liver Transplantation</i> , 2000, 6, 362-366.	1.3	17

#	ARTICLE	IF	CITATIONS
343	Hepatitis A, liver transplants and Indigenous communities. Medical Journal of Australia, 2000, 172, 6-7.	0.8	3
344	Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut, 2000, 46, 260-269.	6.1	161
345	Donor fatty (steatotic) liver allografts in orthotopic liver transplantation: a revisit. Transplantation Proceedings, 2000, 32, 2101-2102.	0.3	13
346	Orthotopic liver transplantation for treatment of patients with Budd-Chiari syndrome: a single-center experience. Transplantation Proceedings, 2000, 32, 2206-2207.	0.3	21
347	Primary graft dysfunction after liver transplantation. Transplantation Proceedings, 2000, 32, 2219-2220.	0.3	23
348	Does alcohol directly stimulate pancreatic fibrogenesis? Studies with rat pancreatic stellate cells. Gastroenterology, 2000, 118, 780-794.	0.6	240
349	Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus. Journal of Hepatology, 2000, 32, 126-134.	1.8	56
350	Posttransplant hepatitis C virus quasispecies and cholestatic hepatitis. Hepatology, 2000, 32, 1182.	3.6	2
351	Post Proline Cleaving Peptidases Having DP IV Like Enzyme Activity. , 2000, 477, 103-109.		18
352	Relating Structure to Function in the Beta-Propeller Domain of Dipeptidyl Peptidase IV. , 2000, 477, 89-95.		10
353	A LARGE, SINGLE CENTER INVESTIGATION OF THE IMMUNOGENETIC FACTORS AFFECTING LIVER TRANSPLANTATION. Transplantation, 2000, 69, 1491-1498.	0.5	59
354	EARLY UP-REGULATION OF MACROPHAGES AND MYOFIBROBLASTS. Transplantation, 2000, 69, 2658-2662.	0.5	84
355	Liver transplantation in chronic hepatitis B and C. Journal of Gastroenterology and Hepatology (Australia), 2000, 15 Suppl, E172-4.	1.4	3
356	Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis. Gut, 1999, 44, 534-541.	6.1	528
357	An active liver transplant programme for hepatocellular carcinoma in cirrhotic patients: is it justified?. Clinical Transplantation, 1999, 13, 531-535.	0.8	14
358	Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted $\beta$ propeller domain. FEBS Journal, 1999, 266, 798-810.	0.2	83
359	LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS. ANZ Journal of Surgery, 1999, 69, 798-801.	0.3	9
360	Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology, 1999, 29, 1768-1778.	3.6	264

#	ARTICLE	IF	CITATIONS
361	Nonspecificity of monoclonal antibody tordji-22 for the detection of hepatitis C virus in liver transplant recipients with cholestatic hepatitis. <i>Liver Transplantation</i> , 1999, 5, 40-45.	1.9	8
362	Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. <i>Liver Transplantation</i> , 1999, 5, 407-413.	1.9	62
363	Lamivudine therapy in patients undergoing liver transplantation for hepatitis b virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immu. <i>Liver Transplantation</i> , 1999, 5, 512-519.	1.9	110
364	Two highly conserved glutamic acid residues in the predicted $\hat{I}^2$ propeller domain of dipeptidyl peptidase IV are required for its enzyme activity. <i>FEBS Letters</i> , 1999, 458, 278-284.	1.3	108
365	Activation of Pancreatic Stellate Cells in Human and Experimental Pancreatic Fibrosis. <i>American Journal of Pathology</i> , 1999, 155, 1087-1095.	1.9	382
366	VASCULAR ENDOTHELIAL GROWTH FACTOR EXPRESSION IN HUMAN CHRONIC RENAL ALLOGRAFT REJECTION1. <i>Transplantation</i> , 1999, 67, 929-933.	0.5	73
367	IS THE T HELPER 1/T HELPER 2 PARADIGM OF ALLOGRAFT TOLERANCE DEAD OR HAS IT JUST BEEN TURNED UPSIDE DOWN?. <i>Transplantation</i> , 1999, 68, 1229-1230.	0.5	1
368	EVIDENCE THAT APOPTOSIS OF ACTIVATED T CELLS OCCURS IN SPONTANEOUS TOLERANCE OF LIVER ALLOGRAFTS AND IS BLOCKED BY MANIPULATIONS WHICH BREAK TOLERANCE1. <i>Transplantation</i> , 1999, 68, 1736-1745.	0.5	95
369	High-dose/activation-associated tolerance model for allografts: lessons from spontaneous tolerance of transplanted livers. <i>Current Opinion in Organ Transplantation</i> , 1999, 4, 58.	0.8	17
370	Cholestatic hepatitis after liver transplantation is associated with persistently high serum hepatitis C virus RNA levels. <i>Liver Transplantation</i> , 1998, 4, 15-21.	1.9	100
371	The effect of ethanol on pancreatic enzymesâ€“a dietary artefact?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1998, 1379, 314-324.	1.1	19
372	Single-center experience of combined liver and kidney transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 3256-3257.	0.3	6
373	Donor fatty (steatotic) liver allografts in orthotopic liver transplantation. <i>Transplantation Proceedings</i> , 1998, 30, 3286-3287.	0.3	27
374	Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture. <i>Gut</i> , 1998, 43, 128-133.	6.1	812
375	Cytochrome P4502E1 is present in rat pancreas and is induced by chronic ethanol administration. <i>Gut</i> , 1998, 42, 426-430.	6.1	66
376	Paradoxical early immune activation during acceptance of liver allografts compared with rejection of skin grafts in a rat model of transplantation. <i>Immunology</i> , 1998, 95, 257-263.	2.0	31
377	KINETICS OF INTRAGRAFT CYTOKINE EXPRESSION, CELLULAR INFILTRATION, AND CELL DEATH IN REJECTION OF RENAL ALLOGRAFTS COMPARED WITH ACCEPTANCE OF LIVER ALLOGRAFTS IN A RAT MODEL. <i>Transplantation</i> , 1998, 65, 1370-1377.	0.5	70
378	REPLY TO "CHIMERISM AND CLONAL EXHAUSTION". <i>Transplantation</i> , 1998, 66, 273.	0.5	0

#	ARTICLE	IF	CITATIONS
379	Atherosclerosis of the liver allograft. <i>Journal of Hepatology</i> , 1997, 27, 592-598.	1.8	7
380	Chronic ethanol administration decreases rat pancreatic GP2 content. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1997, 1336, 89-98.	1.1	19
381	ABO BLOOD GROUP INCOMPATIBILITY IN LIVER TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE. <i>ANZ Journal of Surgery</i> , 1997, 67, 275-278.	0.3	18
382	Liver transplantation. <i>Australian and New Zealand Journal of Medicine</i> , 1997, 27, 371-378.	0.5	3
383	Hepatitis C virus genotypes in a cohort of Australian blood donors and haemophiliac and liver transplant patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 182-187.	1.4	9
384	Liver transplantation for hepatitis C-associated cirrhosis in a single Australian centre: Referral patterns and transplant outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 453-459.	1.4	15
385	Quantitative reverse transcriptase-PCR amplification of cytokine mRNA in liver biopsy specimens using a non-competitive method. <i>Immunology and Cell Biology</i> , 1997, 75, 142-147.	1.0	27
386	Microchimerism and transplant tolerance. <i>Trends in Immunology</i> , 1997, 18, 455-456.	7.5	9
387	Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. <i>Journal of Viral Hepatitis</i> , 1997, 4, 395-409.	1.0	109
388	Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming growth factor $\beta$ in a bile duct ligated rat model of cirrhosis. <i>Hepatology</i> , 1997, 26, 624-633.	3.6	89
389	Recurrence of nonalcoholic steatohepatitis (NASH) post-liver transplantation. <i>Liver Transplantation</i> , 1997, 3, 683-683.	1.9	8
390	Molecular Analyses of Human and Rat Dipeptidyl Peptidase IV. <i>Advances in Experimental Medicine and Biology</i> , 1997, 421, 161-169.	0.8	10
391	Standard Liver Function Tests and Their Limitations: Selectivity and sensitivity of individual serum bile acid levels in hepatic dysfunction. , 1997, , 178-203.		2
392	High-Dose/Activation-Associated Tolerance. <i>Transplantation</i> , 1997, 64, 1377-1382.	0.5	95
393	Both ethanol and protein deficiency increase messenger RNA levels for pancreatic lithostathine. <i>Life Sciences</i> , 1996, 58, 485-492.	2.0	16
394	Multiple endoscopies in a Sydney blood donor found positive for hepatitis B and C antibodies. <i>Medical Journal of Australia</i> , 1996, 164, 571-571.	0.8	9
395	Biliary strictures after liver transplantation: Clinical picture, correlates and outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 21-25.	1.4	46
396	Case Report: Delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996, 11, 734-737.	1.4	34

#	ARTICLE	IF	CITATIONS
397	GIANT CAVERNOUS HAEMANGIOMA: A RARE INDICATION FOR LIVER TRANSPLANTATION. ANZ Journal of Surgery, 1996, 66, 122-124.	0.3	29
398	Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology, 1996, 23, 676-687.	3.6	121
399	Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology, 1996, 24, 759-765.	3.6	394
400	Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology, 1996, 24, 1371-1378.	3.6	76
401	Retransplantation for precore mutant-related chronic hepatitis B infection: Prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy. Liver Transplantation, 1996, 2, 472-474.	1.9	7
402	Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology, 1996, 24, 759-765.	3.6	55
403	Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology, 1996, 24, 1371-1378.	3.6	10
404	TOLERANCE TO RAT LIVER ALLOGRAFTS. Transplantation, 1996, 62, 1725-1730.	0.5	132
405	Tolerance to rat liver allografts. III. Donor cell migration and tolerance-associated cytokine production in peripheral lymphoid tissues. Journal of Immunology, 1996, 156, 4925-31.	0.4	94
406	DELETION OF SPONTANEOUS RAT LIVER ALLOGRAFT ACCEPTANCE BY DONOR IRRADIATION. Transplantation, 1995, 60, 233-236.	0.5	160
407	Hypothalamicâ€pituitaryâ€testicular function in endâ€stage nonâ€alcoholic liver disease before and after liver transplantation. Clinical Endocrinology, 1995, 43, 331-337.	1.2	82
408	Severe hemolysis due to anti-D in a D-negative recipient of an orthotopic liver transplant. Transfusion, 1995, 35, 277-278.	0.8	3
409	Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology, 1995, 21, 14-18.	3.6	83
410	Increased serum levels of dipeptidyl peptidase IV (CD26) in rats undergoing liver regeneration. International Hepatology Communications, 1995, 4, 165-174.	0.7	11
411	Effects of ethanol and protein deficiency on pancreatic digestive and lysosomal enzymes.. Gut, 1995, 36, 287-293.	6.1	46
412	Fulminant hepatic failure post liver transplantation: clinical syndromes, correlations and outcomes. Transplant International, 1995, 8, 20-26.	0.8	2
413	Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology, 1995, 21, 14-18.	3.6	9
414	Liver transplantation: a decade later. Australian Family Physician, 1995, 24, 365-9; 372-4.	0.5	0



#	ARTICLE	IF	CITATIONS
415	Ethanol-induced alterations in messenger RNA levels correlate with glandular content of pancreatic enzymes. <i>Translational Research</i> , 1995, 125, 634-40.	2.4	30
416	Liver transplantation for alcoholic cirrhosis: outcomes and difficulties in patient selection. <i>Transplantation Proceedings</i> , 1995, 27, 2147.	0.3	0
417	Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. <i>Hepatology</i> , 1995, 21, 14-8.	3.6	11
418	Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis. <i>Gastroenterology</i> , 1994, 107, 789-798.	0.6	102
419	Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl) Tj ETQq1 1 0.784314 rgBT /Overlock 169	1.2	169
420	Exon eight APC mutations account for a disproportionate number of familial adenomatous polyposis families. <i>Human Mutation</i> , 1994, 3, 12-18.	1.1	10
421	Daily determination of individual serum bile acids allows early detection of hepatic allograft dysfunction. <i>Hepatology</i> , 1994, 20, 1458-1464.	3.6	20
422	Transvenous intrahepatic porto-systemic shunt (TIPSS): a new treatment for portal hypertension. <i>Australian and New Zealand Journal of Medicine</i> , 1994, 24, 133-135.	0.5	3
423	Anti-neutrophil cytoplasmic antibody: A prognostic indicator in primary sclerosing cholangitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1994, 9, 40-44.	1.4	63
424	Osteoporosis in Chronic Liver Disease: Pathogenesis, Risk Factors, and Management. <i>Digestive Diseases</i> , 1994, 12, 223-231.	0.8	65
425	Histopathological prediction of hepatitis B recurrence in liver allografts. <i>Pathology</i> , 1994, 26, 251-256.	0.3	2
426	TOLERANCE TO RAT LIVER ALLOGRAFTS. <i>Transplantation</i> , 1994, 57, 1349-1357.	0.5	57
427	Tolerance to rat liver allografts. I. Differences between tolerance and rejection are more marked in the B cell compared with the T cell or cytokine response. <i>Transplantation</i> , 1994, 57, 1349-57.	0.5	9
428	Detection of serum hepatitis C virus RNA in HCV antibody-seropositive volunteer blood donors. <i>Hepatology</i> , 1993, 18, 485-490.	3.6	45
429	Liver transplantation for primary sclerosing cholangitis versus primary biliary cirrhosis: A comparison of complications and outcome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 238-243.	1.4	21
430	Hypothalamic-pituitary adrenal function in end-stage non-alcoholic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 247-253.	1.4	61
431	Dipeptidyl peptidase IV is down-regulated in rat hepatoma cells at the mRNA level. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 142-145.	1.4	11
432	Tumour suppressor genes and colorectal neoplasia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 174-184.	1.4	7

#	ARTICLE	IF	CITATIONS
433	Selection of patients for liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 185-194.	1.4	15
434	A follow up of 53 adult patients alive beyond 2 years following liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 1993, 8, 569-573.	1.4	21
435	Intragraft cytokine mRNA levels in human liver allograft rejection analysed by reverse transcription and semiquantitative polymerase chain reaction amplification. Transplant Immunology, 1993, 1, 253-261.	0.6	56
436	Allele non-amplification: a source of confusion in linkage studies employing microsatellite polymorphisms. Human Molecular Genetics, 1993, 2, 289-291.	1.4	61
437	EVIDENCE THAT PORTAL TRACT MICROVASCULAR DESTRUCTION PRECEDES BILE DUCT LOSS IN HUMAN LIVER ALLOGRAFT REJECTION. Transplantation, 1993, 56, 69-74.	0.5	87
438	Detection of serum hepatitis C virus RNA in HCV antibody-seropositive volunteer blood donors. Hepatology, 1993, 18, 485-90.	3.6	6
439	The first five years' clinical experience of the Australian National Liver Transplantation Unit. Medical Journal of Australia, 1992, 156, 9-16.	0.8	18
440	Risk estimation in familial adenomatous polyposis using DNA probes linked to the familial adenomatous polyposis gene.. Gut, 1992, 33, 530-534.	6.1	9
441	Dinucleotide repeat polymorphism at the D5S134 locus linked to the adenomatous polyposis coli (APC) gene. Human Molecular Genetics, 1992, 1, 655-655.	1.4	11
442	Sclerosing cholangitis and biliary tract calculi--primary or secondary?. Gut, 1992, 33, 1376-1380.	6.1	38
443	Sulfasalazine-Induced Fulminant Hepatic Failure. Journal of Clinical Gastroenterology, 1992, 14, 132-135.	1.1	34
444	Striking variability of hepatic copper levels in fulminant hepatic failure. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 396-398.	1.4	25
445	Thrombocytopenia post liver transplantation. Journal of Hepatology, 1992, 16, 16-22.	1.8	78
446	SUCCESSFUL REVERSAL OF PRIMARY GRAFT NON-€FUNCTION IN A LIVER TRANSPLANT PATIENT TREATED WITH PROSTAGLANDIN E<sub>1</sub>. ANZ Journal of Surgery, 1992, 62, 314-316.	0.3	9
447	Altered zonal expression of the CD26 antigen (dipeptidyl peptidase IV) in human cirrhotic liver. Hepatology, 1992, 15, 1048-1053.	3.6	50
448	Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-€positive volunteer blood donors. Medical Journal of Australia, 1992, 157, 231-233.	0.8	24
449	Hepatitis C infection in liver transplant patients. Transplantation Proceedings, 1992, 24, 2256.	0.3	4
450	Liver allograft rejection: analysis of OKT3 rescue therapy. Transplantation Proceedings, 1992, 24, 2250-1.	0.3	0

#	ARTICLE	IF	CITATIONS
451	Identification of cytokine protein expression in human liver allograft rejection: methods development and expression of IL-1 beta, IL-6, IFN-gamma, and basic fibroblast growth factor. Transplantation Proceedings, 1992, 24, 2310-2.	0.3	3
452	Hepatic transplantation for hepatitis B-associated liver disease. Transplantation Proceedings, 1992, 24, 194-5.	0.3	1
453	Inflammatory Pseudotumor of the Liver Causing Biliary Obstruction. Journal of Clinical Gastroenterology, 1991, 13, 338-341.	1.1	30
454	Expression of the rat CD26 Antigen (dipeptidyl peptidase IV) on subpopulations of rat lymphocytes. Cellular Immunology, 1991, 134, 205-215.	1.4	65
455	Bone loss after liver transplantation. Hepatology, 1991, 14, 613-619.	3.6	182
456	Bone loss after liver transplantation. Hepatology, 1991, 14, 613-619.	3.6	31
457	Acute and subacute fulminant hepatic failure: the role of liver transplantation. Medical Journal of Australia, 1991, 154, 724-728.	0.8	27
458	Identification of the bile canalicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV: An analysis by tissue distribution, purification and N-terminal amino acid sequence. Hepatology, 1990, 11, 534-544.	3.6	73
459	A quantitative analysis of T lymphocyte populations in human liver allografts undergoing rejection: The use of monoclonal antibodies and double immunolabeling. Hepatology, 1990, 12, 1305-1313.	3.6	61
460	Characterization of the rat CD26 antigen. Transplantation Proceedings, 1990, 22, 2103-4.	0.3	1
461	Determinants of successful liver transplantation. Transplantation Proceedings, 1990, 22, 2144-5.	0.3	4
462	Development of chronic hepatocerebral degeneration eight years after a distal splenorenal (Warren) shunt. Gut, 1989, 30, 1419-1423.	6.1	4
463	Clinicopathological approach to human liver allograft dysfunction. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 467-477.	1.4	6
464	DANAZOL AND HEPATIC NEOPLASIA: A CASE REPORT. Australian and New Zealand Journal of Medicine, 1989, 19, 733-735.	0.5	13
465	DECISION-MAKING IN 100 PATIENTS REFERRED TO THE AUSTRALIAN NATIONAL LIVER TRANSPLANTATION UNIT. Australian and New Zealand Journal of Medicine, 1989, 19, 132-137.	0.5	4
466	Cell surface phenotype of mononuclear cells infiltrating bile ducts during acute and chronic liver allograft rejection. Transplantation Proceedings, 1989, 21, 2201-2.	0.3	7
467	Improved survival after liver transplantation for primary biliary cirrhosis. Transplantation Proceedings, 1989, 21, 3788-9.	0.3	2
468	Human liver allograft rejection: severity, prognosis, and response to treatment. Transplantation Proceedings, 1989, 21, 3792-3.	0.3	5

#	ARTICLE	IF	CITATIONS
469	Liver Graft Revascularization by Donor Portal Vein Arterialization Following "No Touch" Donor Hepatectomy. <i>HPB Surgery</i> , 1988, 1, 57-66.	2.2	14
470	The gene for MRC OX-2 membrane glycoprotein is localized on human chromosome 3. <i>Immunogenetics</i> , 1987, 25, 133-135.	1.2	36
471	Characterization of the human homolog of the rat MRC OX-2 membrane glycoprotein. <i>Immunogenetics</i> , 1987, 25, 329-335.	1.2	55
472	Relationship between hepatitis B virus DNA in blood and serological markers of hepatitis B infection. <i>Medical Journal of Australia</i> , 1986, 144, 351-355.	0.8	15
473	Regulation of antibody production by an antigen-specific EBV-transformed B-lymphoblastoid cell line: effect of high-dose antigen and antigen-pulsed T cells. <i>Immunology</i> , 1986, 58, 597-602.	2.0	2
474	Neuronal/lymphoid membrane glycoprotein MRC OX-2 is a member of the immunoglobulin superfamily with a light-chain-like structure. <i>Biochemical Society Symposia</i> , 1986, 51, 149-57.	2.7	50
475	Significance of serum and hepatic markers of hepatitis B viral infection in HBsAg-positive and HBsAg-negative chronic active hepatitis. <i>Hepatology</i> , 1985, 5, 50-53.	3.6	15
476	T cell-replacing factor in specific antibody responses to influenza virus by human blood B cells. <i>European Journal of Immunology</i> , 1985, 15, 52-59.	1.6	17
477	Antigen-specific suppression of anti-influenza antibody production in man. Possible role of a membrane-antigen complex. <i>European Journal of Immunology</i> , 1985, 15, 282-290.	1.6	5
478	Long-term survival with tumor regression in androgen-induced liver tumors. <i>Cancer</i> , 1985, 56, 2622-2626.	2.0	82
479	THE ROLE OF HEPATITIS B VIRUS IN THE ETIOLOGY OF HEPATOCELLULAR CARCINOMA IN AUSTRALIA. <i>Australian and New Zealand Journal of Medicine</i> , 1983, 13, 605-607.	0.5	9
480	The Importance of Hepatitis B Infection in the Aetiology of Chronic Hepatitis: A Sydney Hospital Experience. <i>Australian and New Zealand Journal of Medicine</i> , 1982, 12, 19-21.	0.5	5
481	PROGNOSTIC SIGNIFICANCE OF JAUNDICE AFTER RENAL TRANSPLANTATION. <i>Australian and New Zealand Journal of Medicine</i> , 1980, 10, 107-108.	0.5	1
482	CHRONIC HEPATITIS-AETIOLOGICAL CONSIDERATIONS. <i>Australian and New Zealand Journal of Medicine</i> , 1980, 10, 112-112.	0.5	0
483	ACUTE HEPATITIS B IN A METROPOLITAN POPULATION. <i>Medical Journal of Australia</i> , 1979, 2, 333-335.	0.8	4
484	Emerging Patterns of Hepatitis B Chronic Liver Disease in Australia. <i>Australian and New Zealand Journal of Medicine</i> , 1979, 9, 359-364.	0.5	1